Intuitive Surgical (NASDAQ:ISRG) VP Fredrik Widman Sells 2,067 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) VP Fredrik Widman sold 2,067 shares of the business’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $550.00, for a total transaction of $1,136,850.00. Following the sale, the vice president directly owned 473 shares in the company, valued at approximately $260,150. This trade represents a 81.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $547.78 on Friday. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The firm’s 50 day moving average price is $470.16 and its 200 day moving average price is $500.23. The firm has a market cap of $196.37 billion, a PE ratio of 72.46, a PEG ratio of 4.94 and a beta of 1.62.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.41. The company had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.84 earnings per share. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ISRG has been the topic of several research reports. Jefferies Financial Group upped their price target on Intuitive Surgical from $550.00 to $560.00 and gave the company a “hold” rating in a research note on Wednesday, October 22nd. The Goldman Sachs Group raised their price target on shares of Intuitive Surgical from $567.00 to $621.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Truist Financial set a $620.00 price target on Intuitive Surgical and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Intuitive Surgical in a research report on Friday, August 22nd. Finally, Robert W. Baird set a $655.00 price target on shares of Intuitive Surgical in a report on Wednesday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $608.92.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ISRG. Tobam grew its position in Intuitive Surgical by 666.7% during the second quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 40 shares during the period. Kilter Group LLC purchased a new position in shares of Intuitive Surgical in the second quarter valued at $27,000. Greykasell Wealth Strategies Inc. purchased a new stake in shares of Intuitive Surgical in the third quarter worth about $27,000. TD Capital Management LLC boosted its holdings in Intuitive Surgical by 300.0% in the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 45 shares during the period. Finally, 1248 Management LLC bought a new stake in shares of Intuitive Surgical during the 1st quarter valued at about $30,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.